US bans imports from 3 Chinese biotech companies over forced labor allegations

Supreme Court News

US bans imports from 3 Chinese biotech companies over forced labor allegations

The Trump administration announced Wednesday that it will block imports from Chinese biotechnology firm BGI Group and two of its affiliates, citing alleged links to forced labor in Xinjiang, China's far-western ethnic region.

Beginning Thursday, U.S. Customs and Border Protection will stop goods from BGI Group, a major player in genetic sequencing, along with BGI Genomics and MGI Tech. According to the Department of Homeland Security, the companies either source materials from Xinjiang or work with the regional government in the recruitment and movement of forced labor drawn from persecuted ethnic groups there, including Uyghurs. DHS said BGI Group holds controlling stakes in both affiliates.

DHS cites genetic testing in Xinjiang

In its announcement, DHS said credible information, including corporate and government reports, shows the three companies have supported genetic testing in Xinjiang. The department said the collection and analysis of genetic material helps Chinese authorities monitor, surveil and repress ethnic minorities, including through forced labor.

The action falls under the Uyghur Forced Labor Prevention Act, which President Joe Biden signed into law at the end of 2021 in response to allegations of human rights abuses against Uyghurs and other Muslim minorities in Xinjiang. In August, the Trump administration added 43 Chinese companies to the law's blacklist, bringing the total to 187 entities. Homeland Security Secretary Markwayne Mullin has pledged to protect American workers from being undercut by foreign companies that rely on forced labor.

Beijing and BGI push back

China rejected the forced labor accusations and denounced the ban as political manipulation and bullying carried out in the name of human rights. In a statement Thursday morning, China's Ministry of Commerce said the listings contradict the consensus reached by the two countries' leaders, threaten the stability of bilateral trade relations, and that China will take necessary measures to protect its interests. Beijing has long dismissed the Xinjiang allegations as false, describing its policies in the region as counterterrorism and stability efforts.

BGI Group also denied the claims, stating Wednesday that it "has not engaged in any form of forced labor" and opposes forced labor in all forms.

Biotech becomes a new front

The move highlights biotechnology as a growing area of economic and technological rivalry between Washington and Beijing. Last week, the Treasury Department proposed new limits on U.S. investment in biotechnology, artificial intelligence and supercomputing in countries such as China.

BGI Group has drawn scrutiny from U.S. lawmakers and officials for years over concerns that its alleged government ties and access to vast amounts of genetic data could threaten U.S. national security and commercial interests. The company has emphasized that it is privately owned, does not serve patients in the United States and has no access to Americans' genetic data. The Pentagon has designated BGI Group, BGI Genomics and MGI Tech as Chinese military companies.

Congress did not pass a bill that would have barred BGI from working with federally funded medical providers, but late last year it approved a similar measure that did not name specific companies and instead called for a list of biotechnology companies of concern.

The latest trade action comes ahead of an expected meeting next month between Chinese leader Xi Jinping and President Donald Trump in Shenzhen, where BGI Group is headquartered. Xi may also travel to Florida in December for the Group of 20 leaders summit, which would mark a fourth meeting between the two leaders this year as they seek to keep relations steady under a trade truce.

Related listings

Workers’ Compensation Subrogation of Administrative Fees and Costs

When a worker covered by workers’ compensation makes a claim against a third party, the workers’ compensation insurance retains the right to subrogate against any recovery from that third party for all benefits paid to or on behalf of a claimant injured at work. When subrogating for more than basic medical and indemnity benefits, the Texas workers’ compensation subrogation statute provides that “the net amount recovered by a claimant in a third‑party action shall be used to reimburse the carrier for benefits, including medical benefits that have been paid for the compensable injury.” TX Labor Code § 417.002.

In fact, all 50 states provide for similar subrogation. However, none of them precisely outlines which payments or costs paid by a compensation carrier constitute “compensation” and can be recovered. The result is industry-wide confusion and an ongoing debate and argument with claimants’ attorneys over what can and can’t be included in a carrier’s lien for recovery purposes.

In addition to medical expenses, death benefits, funeral costs and/or indemnity benefits for lost wages and loss of earning capacity resulting from a compensable injury, workers’ compensation insurance carriers also expend considerable dollars for case management costs, medical bill audit fees, rehabilitation benefits, nurse case worker fees, and other similar fees. They also incur other expenses in conjunction with the handling and adjusting of workers’ compensation claims. Workers’ compensation carriers typically assert, of course, that, they are entitled to reimbursement for such expenditures when it recovers its workers’ compensation lien. Injured workers and their attorneys disagree.